Bioscience Neutraceuticals Inc. (DEVV) financial statements (2021 and earlier)

Company profile

Business Address 500 NORTH MICHIGAN AVENUE #600
CHICAGO, IL 89015
State of Incorp. NV
Fiscal Year End December 31
SIC 59 - Miscellaneous Retail (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments     14
Cash and cash equivalents     14
Inventory, net of allowances, customer advances and progress billings     55
Inventory     55
Prepaid expense    6  
Total current assets:    669
Noncurrent Assets
TOTAL ASSETS:    669
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:22249372819
Accrued liabilities59464121 1411
Interest and dividends payable311917151296
Other undisclosed accounts payable and accrued liabilities(88)(64)(57)132552
Debt28428282844
Due to related parties 132129107100103104
Other undisclosed current liabilities211855615234646
Total current liabilities:240223214199187181173
Noncurrent Liabilities
Long-term debt and lease obligation4 444  
Long-term debt, excluding current maturities4 444  
Liabilities, other than long-term debt 27     
Accounts payable and accrued liabilities 27     
Other undisclosed noncurrent liabilities (23)   44
Total noncurrent liabilities:4444444
Total liabilities:244227218203191185177
Stockholders' equity
Stockholders' equity attributable to parent(244)(227)(218)(203)(185)(179)(168)
Common stock1111011
Additional paid in capital699562562562133114114
Accumulated deficit(944)(790)(781)(765)(318)(294)(283)
Total stockholders' equity:(244)(227)(218)(203)(185)(179)(168)
TOTAL LIABILITIES AND EQUITY:    669

Income statement (P&L) ($ in thousands)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
Revenues    (6)22
Cost of revenue     (2)(2)
Gross profit:     (0)1
Operating expenses(5)(4)(10)(441)(7)(4)(21)
Other undisclosed operating income17   2  
Operating income (loss):12(4)(10)(441)(5)(5)(20)
Nonoperating expense(12)(5)(5)(6)(6)(6)(6)
Other nonoperating expense (5)(5)(6)(6)(6)(6)
Interest and debt expense(3)  (3)   
Other undisclosed loss from continuing operations before equity method investments, income taxes    (2)  
Loss from continuing operations before equity method investments, income taxes:(4)(9)(15)(450)(13)(11)(27)
Other undisclosed income (loss) from continuing operations before income taxes(151)  32  
Loss from continuing operations:(154)(9)(15)(447)(12)(11)(27)
Other undisclosed loss before gain (loss) on sale of properties    (12)  
Net loss available to common stockholders, diluted:(154)(9)(15)(447)(24)(11)(27)

Comprehensive Income ($ in thousands)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
Net loss:(154)(9)(15)(447)(24)(11)(27)
Comprehensive loss, net of tax, attributable to parent:(154)(9)(15)(447)(24)(11)(27)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: